On October 30, 2018 Shanghai Fosun High Technology (Group) Co., Ltd. ("Fosun High Technology"), a subsidiary of Fosun International Limited (the "Company"), which has issued medium-term notes in February 2018, April 2018, July 2018 and September 2018 respectively, and super commercial paper in June 2018 in the China’s interbank bond market, published its 2018 third quarter report (the "Report") on 30 October 2018, in accordance with the relevant regulations in China (Press release, Fosun Pharma, OCT 30, 2018, View Source [SID1234530388]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The board of directors of the Company (the "Board") would like to draw the attention of its shareholders and the investment public to the following unaudited principal consolidated financial data of Fosun High Technology for the nine months ended 30 September 2018 as set out below in the Report:

Unit: Thousand Yuan Currency: RMB
As at the end of
this reporting period As at the end of last year
Increase/decrease as at
the end of this reporting
period as compared
with the end of last year
(%)
Total assets 288,748,478 236,798,051 21.94%
Equity attributable to
owners of the parent 53,614,661 50,089,794 7.04%
From the beginning of
2018 up to the end of
this reporting period
From the beginning of
last year up to the end of
the same reporting period
of last year
Increase/decrease as
compared with the
same period of last year
(%)
Revenue from operation 34,250,739 23,433,701 46.16%
Profit attributable to
owners of the parent 3,863,135 3,601,006 7.28%